Stockscreener 앱 받기
36.85
0.23%
-0.085
시간 외 거래:
37.01
0.155
+0.42%
전일 마감가:
$36.94
열려 있는:
$37.135
하루 거래량:
5.15M
Relative Volume:
1.47
시가총액:
$10.05B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
20.82
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
-18.82%
1개월 성능:
-15.61%
6개월 성능:
+11.92%
1년 성능:
+58.38%
1일 변동 폭
$36.85
$37.98
1주일 범위
$36.81
$46.43
52주 변동 폭
$23.13
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.85 | 9.94B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Is Exelixis Inc. a Top Dividend Stock to Watch in 2025Entry and Exit Strategy Optimizer Tool Tested - metal.it
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues - MSN
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Call Transcript - Insider Monkey
Exelixis Inc. Forms Double Bottom Pattern — Eyes on BreakoutConservative Long Term Growth Plans Under Review - metal.it
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
U.S. Indexes Decreased Tuesday; Exelixis Posted Biggest Loss - Barron's
Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase - MSN
Exelixis stock price target lowered to $45 at RBC on lifecycle cuts - Investing.com Canada
Truist Securities lowers Exelixis stock price target to $49 on mixed results - Investing.com Canada
Exelixis stock price target raised to $41 from $38 at Stifel on NET launch - Investing.com Canada
Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 HaltExelixis (NASDAQ:EXEL) - Benzinga
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy - Yahoo Finance
Is Exelixis Inc. Forming a Consolidation BaseTop Performing Stock Insights Released Daily - metal.it
Exelixis leans on zanzalintinib as cabozantinib nears patent expiry - S&P Global
Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt - MSN
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
S&P 500 Futures Climb in Premarket Trading; Whirlpool, Exelixis Lag - Barron's
Exelixis fall over 12% after revenue miss, halts zanzalintinib trial By Investing.com - Investing.com India
UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More Market Movers - Barron's
Exelixis stock rating reiterated by JMP analyst despite sales miss - Investing.com Nigeria
Exelixis Shares Plunge 12.14% on Revenue Miss - AInvest
Exelixis 2025 Q2 Earnings Mixed Performance as Net Income Declines 18% - AInvest
Exelixis Q2 Revenue Falls 11 Percent - AOL.com
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - Yahoo Finance
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges By GuruFocus - Investing.com Canada
Exelixis’s SWOT analysis: cabo success, zanza potential drive stock outlook - Investing.com
Exelixis Reports Q2 2025 Financial Results and Updates - TipRanks
Exelixis: Q2 Earnings Snapshot - The Washington Post
Exelixis Beats On Earnings As Cancer Drugs Drive Growth - Finimize
Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025 - Investing.com
Exelixis slides 12% on Q2 miss, pipeline update (EXEL:NASDAQ) - Seeking Alpha
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
After-hours movers: Western Union, Whirlpool, Exelixis, and more By Investing.com - Investing.com Canada
Exelixis (EXEL) Beats Q2 Earnings Estimates - Yahoo Finance
Exelixis Q2 Earnings: Surpassing Expectations Amid Revenue ChallengesNews and Statistics - IndexBox
How strong is Exelixis Inc. company’s balance sheetRetirement Planning Insights For 2025 - jammulinksnews.com
EXELIXIS, INC. SEC 10-Q Report - TradingView
Exelixis shares tumble as revenue miss and weak guidance disappoint - Investing.com Australia
Exelixis shares tumble as revenue miss and weak guidance disappoint By Investing.com - Investing.com India
Exelixis earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Exelixis Q2 2025 Financial Results and Corporate Update - TradingView
Exelixis Q2 adjusted EPS beats expectations - MarketScreener
Should I hold or sell Exelixis Inc. stock in 2025Top Growth Entry Points For Every Investor - jammulinksnews.com
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - sharewise.com
Published on: 2025-07-28 16:17:28 - metal.it
Is it the right time to buy Exelixis Inc. stockSuperior returns - jammulinksnews.com
How many analysts rate Exelixis Inc. as a “Buy”Capitalize on proven trading setups - jammulinksnews.com
Why is Exelixis Inc. stock attracting strong analyst attentionSwing Trade Opportunities From AI Tools - jammulinksnews.com
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with a 30% Revenue Growth Surge - DirectorsTalk Interviews
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.40%
자본화:
|
볼륨(24시간):